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Abstract
Background: Vaccine development against malaria and other complex diseases remains a challenge for the scientific
community. The recent elucidation of the genome, proteome and transcriptome of many of these complex pathogens
provides the basis for rational vaccine design by identifying, on a proteome-wide scale, novel target antigens that are
recognized by T cells and antibodies from exposed individuals. However, there is currently no algorithm to effectively
identify important target antigens from genome sequence data; this is especially challenging for T cell targets. Furthermore,
for some of these pathogens, such as Plasmodium, protein expression using conventional platforms has been problematic
but cell-free in vitro transcription translation (IVTT) strategies have recently proved successful. Herein, we report a novel
approach for proteome-wide scale identification of the antigenic targets of T cell responses using IVTT products.
Principal Findings: We conducted a series of in vitro and in vivo experiments using IVTT proteins either unpurified,
absorbed to carboxylated polybeads, or affinity purified through nickel resin or magnetic beads. In vitro studies in humans
using CMV, EBV, and Influenza A virus proteins showed antigen-specific cytokine production in ELIspot and Cytometric Bead
Array assays with cells stimulated with purified or unpurified IVTT antigens. In vitro and in vivo studies in mice immunized
with the Plasmodium yoelii circumsporozoite DNA vaccine with or without IVTT protein boost showed antigen-specific
cytokine production using purified IVTT antigens only. Overall, the nickel resin method of IVTT antigen purification proved
optimal in both human and murine systems.
Conclusions: This work provides proof of concept for the potential of high-throughput approaches to identify T cell targets
of complex parasitic, viral or bacterial pathogens from genomic sequence data, for rational vaccine development against
emerging and re-emerging diseases that pose a threat to public health.
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Introduction
The development of high throughput techniques to identify the
targets of cellular immunity on a proteome-wide scale will facilitate
the development of vaccines against complex diseases. Almost
all vaccines currently licensed for human use rely on antibody
responses against the target pathogen. None are designed to induce
protective T cell response, yet T cell responses are implicated as
critical in protection against many pathogens, especially those with
an intracellular stage such as the causative agents of malaria,
leishmaniasis and Chagas disease [1,2]. CD4+ T cells also play a
key role in enhancing the pathogen-specific antibody responses [3].
The elucidation of the genome, proteome and transcriptome of
important human pathogens, including the Plasmodium parasite, has
provided a wealth of data that can potentially be mined to identify,
on a proteome-wide scale, novel target antigens recognized by T
cells and antibodies. However, how to effectively mine this data has
proved challenging. In particular, technologies such as conventional
protein expression methodologies which are well established on an
individual antigen basis often cannot be translated directly to a
whole proteome scale.
An important achievement of the scientific community, therefore,
has been the development of technologies that allow the high
throughput expression of recombinant proteins. These In Vitro
Transcription and Translation systems (IVTT) or cell-free systems
offer several advantages over traditional cell-based expression
methods and are suitable for high throughput strategies due to
reduced reaction volumes and process time [4,5,6]. Additional
advantages include easy modification of reaction conditions for
improving production of complex proteins, decreased sensitivity to
product toxicity, and high yield. Importantly, cell-free systems have
proved capable of generating proteins from complex parasites that
have been difficult to produce in traditional cell-based systems, such
as Plasmodium proteins [7,8,9,10]. The most efficient expression to
date has been achieved with an E. coli cell-free system which has
yielded more than 93% efficiency of expression with a panel of 250
P. falciparum (Pf) proteins [11]. Eukaryotic based cell-free systems are
also available with wheat germ, rabbit reticulocytes and insect cells.
The eukaryotic lysate is considered by some to provide a better
platform for production of complex proteins particularly with
regard to post-translational modifications. Recently, up to 75%
efficiency of production of Pf proteins in the wheat germ system
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has been reported [12,13] but this is still less efficient than that
observed with the E. coli system [11].
The combination of these tools with large-scale cloning strategies,
such as recombinatorial cloning, allow the generation of complete
proteomes in vitro for multiple purposes. Several reports have shown
the application of these tools for identifying antibody targets of
complex diseases using protein arrays [11,14,15]. Such studies have
established the feasibility of identifying, from a set of thousands of
antigens, the most immunogenic targets of antibody responses
which may correlate with protection as indicated by clinical disease
stage classification [16] or virus neutralising activity [17].
More challenging is the high throughput elucidation of T cell
targets which is clearly of importance for those diseases where cell
mediated immunity is implicated in protection, as well as for
antibody mediated immunity where T cell help would be
beneficial. Recently, the use of the E. coli based cell-free system
(Rapid Translational system, RTS) for profiling of CD4+ T cell
responses to vaccinia virus in humans was reported [18]. In that
study, 180 predicted open reading frames of the vaccinia genome
were expressed in the RTS system and unpurified RTS reaction
products were tested for recognition by vaccinia virus-enriched T
cell lines derived from 11 Dryvax smallpox vaccines, using 3H-
thymidine proliferation assays. Another study reported the use of
IVTT products affinity purified on protein G-conjugated carbox-
ylate microsphere beads to stimulate proliferative responses of
polyclonal short-term T cell lines from cattle immunised with
purified A. marginale outer membranes [19]. Of note, both studies
used T cell lines, rather than unpurified splenocytes or bulk
peripheral blood mononuclear cells, and neither reported a
systematic evaluation of the T cell screening process.
Herein, we present a series of in vitro and in vivo experiments
designed to demonstrate proof-of-concept for high throughput
identification of antigens recognised by T cell responses in human
or murine systems, using IVTT products unpurified, affinity
purified through nickel resin or magnetic beads, or absorbed in
beads to enhance the cell mediated immunogenicity by promoting
dendritic cell uptake [20,21]. IVTT produced antigens of FluM
and FluHA from Influenza A virus [22], CMVpp65 from
Cytomegalovirus [23] and EBNA3A from Epstein-Barr virus
[24] were assayed using bulk human PBMC for T cell recognition.
Additionally, Plasmodium yoelii circumsporozoite protein (PyCSP)
[25] IVTT products were assayed for antigenicity in vitro using
splenocytes from PyCSP-immunized mice, and for immunogenic-
ity in vivo as assessed by capacity to boost a PyCSP-specific immune
response primed by plasmid DNA. In both human and murine
systems, T cell responses were evaluated by IFN- c ELISpot and
Cytometric Bead Array (CBA) cytokine assays. Robust IFN-c,
TNF-a and IL-10 responses were detected, and IVTT products
affinity purified through nickel resin or magnetic beads were
highly effective. Considering the loss associated with purification,
the nickel resin method proved the most optimal.
Results
Production and yield of IVTT products
Coding sequences were expressed by coupled transcription-
translation in the E. coli cell-free IVTT system. An aliquot of each
reaction mixture was analysed by SDS-PAGE and western blot,
followed by chemiluminescence of the membrane to visualize the
products formed. All four viral (FluHA, FluM, CMVpp65,
EBNA3) and one parasite (PyCSP) recombinants could be
produced using the manufacturer’s recommended conditions.
The average yield of each full-length recombinant, detected using
an anti-HA antibody directed against the C-Terminal HA tag, was
as follow: FluM, 1.15 mg/ml; FluHA, 0.73 mg/ml (two moles of HA
tag per molecule of FLU-HA); CMVpp65, 0.7 mg/ml; EBNA3A,
4 ng/ml; and PyCSP, 0.6 mg/ml (Figures 1A and B and Figure
S1A). Western blot analysis using an antibody directed against the
N-Terminal 6xHIS tag identified the presence of partial products
for each viral recombinant (PyCSP not tested) (Figure S1B).
Solubility analysis showed that a high proportion (at least 70%) of
each recombinant was insoluble. A series of optimization studies
including kinetics of expression (3 hr to 6 hr), reaction tempera-
ture (16uC, 25uC, 30uC), speed (stationary, 300 rpm, 600 rpm),
addition of protease inhibitor cocktails, or addition of non-ionic
detergents to promote protein solubilisation (Triton X-110 or
Figure 1. Recombinants produced using E. coli cell-free IVTT system. Western Blot and quantification of (A) viral antigens FluM, FluHA,
CMVpp65 or EBNA3A and (B) parasite antigen PyCSP pIVEX HisHA IVTT products, probed with mAb against the C-terminal HA tag. Whole IVTT
extracts (5 ml) of each antigen were run on a 12% NUPAGE gel, transferred to a PVDF membrane, and probed with anti-HA HRP antibody (1:500
dilution). Protein expression was quantitated against an IVTT-produced recombinant P. falciparum (PF14_0051) protein of known concentration
expressing the same N-terminal 6xHis and C-terminal HA tags. Yields for each full length antigen were as follow: FluM, 1.15 mg/ ml; FluHA, 0.73 mg/ ml;
CMVpp65, 0.7 mg/ ml; EBNA3A, 4 ng/ ml; and PyCSP, 0.6 mg/ ml.
doi:10.1371/journal.pone.0027666.g001
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Triton X-114) had no significant effect on the yield of full-length
protein or partial products, or protein solubility (data not
presented). Accordingly, a standard protocol of 4 hrs incubation
at 30uC and 300 rpm was adopted for the IVTT reactions. IVTT
products were used either unpurified (whole extract), associated to
Polybeads or ProteinG beads, or purified using NI-NTA resin or
MagneHis Ni-particles. The MagneHis purification method was
associated with a very low recovery yield and this yield was much
lower than with the NI-NTA system. For example, for PyCSP, the
loss associated with purification using Ni-NTA or MagneHis was
approximately 30% and 80% respectively.
We also evaluated production of the viral antigens in an insect
cell based cell-free system (PyCSP not tested). In a limited number
of attempts using the manufacturer’s recommended conditions,
only two of the four viral protein targets (FluM and CMVpp65)
could be produced in this eukaryotic system. However, in contrast
to results with the E. coli system, solubility analysis showed
that at least 90% of the recombinants were soluble and partial
polypeptides were not detected (Figure 2).
In summary, all FluHA, FluM, CMVpp65, EBNA3 and PyCSP
IVTT recombinants could be produced in the E. coli cell-free
IVTT system, using the manufacturer’s recommended conditions.
However, at least 70% of each IVTT product was insoluble. In
contrast, only two of the four viral antigens could be produced in
the insect cell based system but in this system at least 90% of the
product was soluble.
In vitro stimulation of PyCSP antigen-specific T cell
response using IVTT products
The ability of IVTT products to stimulate an antigen-specific T cell
response in vitro was evaluated in the P. yoelii CSP model. Splenocytes
from mice (n = 5/group) immunized with VR2516 PyCSP plasmid
DNA or VR1020 control plasmid were stimulated in vitro with
unpurified rPyCSP IVTT; rPyCSP IVTT associated to Polybeads or
ProteinG beads; rPyCSP IVTT purified using NI-NTA resin,
MagneHis Ni-particles, or anti-HIS; or synthetic peptides represent-
ing defined T cell epitopes from PyCSP. Antigen-specific cytokine
production was assayed using IFN-c ELISpot or CBA assays.
The number of IFN-c SFCs was significantly higher with
splenocytes from VR2516 immunized mice as compared to
VR1020 immunized mice when stimulated in vitro with PyCSP IVTT
purified using NI-NTA resin (p= 0.013), MagneHis Ni-particles
(p= 0.015) or PyCSP synthetic peptides (p= 0.003) (Figure 3A). There
was no significant difference when splenocytes were stimulated with
either unpurified IVTT or unpurified IVTT associated to Polybeads
or Protein G beads (Figure 3A). Unexpectedly, the use of wells pre-
coated with anti-HIS mAb to capture the tagged proteins was poorly
effective with no difference noted between the VR2516 and VR1020
groups. Markedly higher background reactivity was noted with the
unpurified or bound IVTT preparations as compared to the purified
preparations, presumably due to the presence of high levels of LPS
and proteins in the E. coli extract (Figure 3A).
Consistent with the ELISpot data, the amount of secreted IFN-c
by CBA in cultures of splenocytes from VR2516 versus VR1020
immunized mice was significantly greater in cultures stimulated in
vitro with PyCSP IVTT purified using NI-NTA resin (p = 0.005) or
MagneHis Ni-particles (p = 0.003) or PyCSP synthetic peptides
(p = 0.02) (Figure 3B). There was no significant difference when
splenocytes were stimulated with either unpurified IVTT or
unpurified IVTT associated to Polybeads or Protein G beads. No
significant antigen-specific IL-10, TNF-a or IL-6 responses could
be detected upon stimulation with purified or unpurified IVTT
products; responses were detected upon stimulation with PyCSP
peptides (Figures S2A and S2B; data not presented for IL-6).
In summary, robust antigen-specific IFN-c responses from
splenocytes of mice immunized with PyCSP plasmid DNA could
be induced following in vitro stimulation with IVTT products
purified by either NI-NTA resin or MagneHis Ni-particles, but not
by unpurified IVTT reactions or IVTT products associated to
Polybeads or Protein beads. There was no significant difference
between responses induced by NI-NTA resin and MagneHis Ni-
particle purifications, but there was a much greater loss of
recombinant associated with purification using the MagneHis Ni-
particles as compared to NI-NTA resin. In general, responses
induced by stimulation with the purified PyCSP IVTT products
were comparable to responses induced by stimulation with a pool of
synthetic peptides representing defined T cell epitopes from PyCSP.
In vivo stimulation of PyCSP antigen-specific T cell
response using IVTT products
We next evaluated the capacity of unpurified and purified
IVTT products to boost PyCSP primed immune responses in vivo.
Figure 2. Recombinants produced using the insect cell extract
IVTT system. Western Blot of viral antigen pIVEX HisHA IVTT products
probed with anti-HA HRP antibody (1:500). Lane 1: negative control
IVTT control reaction. Lanes 2 and 3: FluM, supernatant and whole
extract. Lanes 4 and 5: FluHA supernatant and whole extract. Lanes 6
and 7: CMVpp65 supernatant and whole extract. Lanes 8 and 9: EBNA3A
supernatant and whole extract. FluM and CMVpp65 were expressed
efficiently and as soluble proteins using this system. FluHA and EBNA3A
were not expressed. PyCSP, not tested.
doi:10.1371/journal.pone.0027666.g002
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Mice (n = 5/group) were primed with VR2516 PyCSP plasmid
DNA and then boosted in vivo with unpurified rPyCSP IVTT,
PyCSP IVTT associated to Polybeads or ProteinG beads, or
PyCSP IVTT purified using NI-NTA resin or MagneHis Ni-
particles, all adjuvanted with Alum. Splenocytes were stimulated in
vitro with A20 target cells transfected with VR2516 PyCSP DNA or
A20 cells pulsed with PyCSP synthetic peptides. Antigen-specific
cytokine production was assayed using IFN-c ELISpot or CBA
assays.
IFN-c responses were detected by both ELISpot and CBA
following in vivo boosting with PyCSP DNA (p,0.001 for ELISpot
and p,0.05 for CBA) or PyCSP IVTT purified using either NI-
NTA resin or MagneHis Ni-particles (p,0.01 for ELISpot), as
compared to Alum control (Figures 4A and 4B). Responses
stimulated by purified IVTT products were almost as robust as
those stimulated with PyCSP DNA. Low responses were noted
when mice were boosted with unpurified whole extract or
unpurified IVTT associated to either Polybeads or ProteinG beads.
Significant IL-10 responses were also detected following
boosting with PyCSP IVTT purified using either NI-NTA resin
(p,0.001) or MagneHis Ni-particles (p,0.001), as compared to
Alum control, but not following boosting with unpurified whole
extract or IVTT products associated to either Polybeads or
ProteinG beads, or with PyCSP DNA (Figure S2C). TNF-a
responses were not significantly different from the controls for any
of the conditions (Figure S2D). IL-2 responses were induced only
by purified IVTT products (data not presented). No significant
responses were detected for other cytokines assayed using the
CBA assay.
In summary, consistent with the results following in vitro
stimulation with IVTT products, robust antigen-specific IFN-c
responses could be induced by in vivo boosting with PyCSP IVTT
products purified by either NI-NTA resin or MagneHis Ni-
particles, but not by unpurified IVTT reactions or IVTT products
associated to Polybeads or ProteinG beads. There was no
significant difference between purification with either NI-NTA
resin or MagneHis Ni-particle, nor between purified IVTT
products and plasmid DNA. The magnitude of Th1 (IFN-c and
TNF-a) responses stimulated in vitro by purified IVTT PyCSP
products were similar to those stimulated by PyCSP plasmid DNA.
In vivo stimulation of PyCSP antigen-specific antibody
response using IVTT products
The ability of IVTT products to stimulate an antigen-specific
antibody response was also determined. Sera from mice (n =
5/group) primed with VR2516 PyCSP plasmid DNA and
boosted in vivo with rPyCSP IVTT purified using NI-NTA resin
plus Alum were evaluated by ELISA against synthetic peptide
representing the recombinant PyCSP protein. Data demonstrated
that in vivo boosting with PyCSP IVTT products significant
Figure 3. In vitro evaluation of IVTT proteins. PyCSP specific IFN-c secretion by splenocytes of mice immunized with VR2516 PyCSP plasmid DNA
or VR1020 control DNA. Splenocytes were cultured with unpurified rPyCSP IVTT; rPyCSP IVTT associated to Polybeads or ProteinG beads; rPyCSP IVTT
purified using NI-NTA resin, MagneHis Ni-particles, or anti-HIS; or synthetic peptides representing defined T cell epitopes from PyCSP (positive
control), as indicated. (A) IFN-c ELISpot responses (spot forming cells, SFC per million splenocytes) of cultured splenocytes, analysed after 36 hrs
stimulation. (B) secreted IFN-c in culture supernatant, measured by Cytometric Bead Array (CBA) after 48 hrs stimulation. Data are presented as mean
+/- standard deviation of 5 mice/group. *P,0.05 and **P,0.01 compared to VR1020 control.
doi:10.1371/journal.pone.0027666.g003
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boosted antigen-specific antibody responses relative to responses
induced by PyCSP plasmid DNA in the absence of boosting
(Figure 5).
In vitro stimulation of viral antigen-specific T cell
responses by human PBMCs using IVTT products
The antigenicity of IVTT products in human PBMC cultures
was next evaluated. The viral antigens FluM, FluHA, CMVpp65
and EBNA3A produced by IVTT were used unpurified,
associated to Polybeads or ProteinG beads, or purified using NI-
NTA resin or MagneHis Ni-particles to assay recall cytokine
responses from PBMCs of 10 healthy humans by IFN-c ELISpot
or CBA.
Consistent with the results in murine system, significant IFN-c
ELISpot responses (p,0.05) were detected with all IVTT antigens
purified using NI-NTA resin (Figure 6A) and for all antigens
purified using MagneHis Ni-particles except FluM (Figure 6B) (as
compared to PBS); the lack of responses with FluM was attributed
to a low yield post MagneHis Ni purification (data not presented).
Unexpectedly, significant IFN-c ELISpot responses were also
noted with all IVTT viral antigens used unpurified (compared
to empty pIVEX HisHA IVTT) (Figure 6C) or associated to
Figure 4. In vivo evaluation of IVTT proteins. PyCSP specific IFN-c responses of mice immunized with VR2516 PyCSP plasmid DNA and boosted
in vivo with IVTT products: unpurified rPyCSP IVTT; rPyCSP IVTT associated to Polybeads or ProteinG beads; or rPyCSP IVTT purified using NI-NTA resin
or MagneHis Ni-particles. All IVTT products were formulated with Alum adjuvant. Parallel groups of mice were boosted with either Alum only or
VR2516 as controls. Splenocytes were cultured with A20 cells transfected with VR2516 PyCSP plasmid DNA or A20 cells pulsed with synthetic peptides
representing defined PyCSP T cell epitopes. A) IFN-c ELISpot responses (spot forming cells, SFC per million splenocytes) of cultured splenocytes,
analysed after 36 hrs stimulation. (B) secreted IFN-c in culture supernatant, measured by Cytometric Bead Array (CBA) after 48 hrs stimulation. Data
are presented as mean +/- standard deviation of 5 mice/group. *P,0.05, **P,0.01 and ***P,0.001 compared to negative control (Alum only boost).
doi:10.1371/journal.pone.0027666.g004
Figure 5. Antibody response induced by PyCSP IVTT protein.
PyCSP specific antibody responses of mice immunized with VR2516
PyCSP plasmid DNA and boosted in vivo with VR2516 or rPyCSP IVTT
purified using NI-NTA resin and formulated with Alum adjuvant. Serially
diluted sera samples were assayed against recombinant PyCSP capture
antigen. Data are presented as OD450 at each dilution, mean +/-
standard deviation of 5 mice/group.
doi:10.1371/journal.pone.0027666.g005
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ProteinG beads (compared to empty pIVEX HisHA IVTT
associated with ProteinG beads) (Figure 6D), but only for only
two or the four IVTT viral antigens associated with Polybeads
(FluM and FluHA; compared to empty pIVEX HisHA IVTT
associated with Polybeads) (Figure 6E).
Also consistent with the murine system, no significant responses
were detected for any antigens when the ELISpot wells were pre-
coated with anti-His mAb to capture the His-tagged IVTT
proteins. The background responses with the unpurified or bound
IVTT products were greater than for purified IVTT products,
Figure 6. Antigen-specific IFN-c ELIspot responses by human PBMC stimulated with IVTT-proteins. PBMCs were cultured with IVTT-
produced FluM, FluHA, pp65 and EBNA3A purified using (A) NI-NTA nickel resin or (B) MagneHis Ni-particles; (C) unpurified; associated to (D) ProteinG
beads or (E) Polybeads; or (F) added to wells precoated with Anti-His. Negative controls were medium only, unpurified whole extract, and whole
extract associated to Polybeads or Protein G beads; positive control was CEF peptide pool. IFN-c ELIspot responses (spot forming cells, SFC) of
cultured PBMCs were analysed after 36 hrs stimulation. Data are presented as mean +/- standard deviation of 10 volunteers. *P,0.05, **P,0.01 and
***P,0.001 compared to negative controls.
doi:10.1371/journal.pone.0027666.g006
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presumably as a result of prior exposure of the human subjects to
E. coli bacteria or presence of LPS. Significant IFN-c responses to
the CEF peptide pool p,0.0001, compared to PBS) were noted for
all subjects (data not presented).
For all viral antigens, robust IFN-c responses were detected
by CBA in cultures stimulated at 1:100 dilution with IVTT
products purified using NI-NTA resin (Figure 7A) or MagneHis
Ni-particles (Figure 7B) but not with purified products at 1:1,000
or 1:10,000 dilutions, presumably due to the low amount of
antigen in culture (Figures 7A and 7B). With unpurified IVTT
products or IVTT antigens associated to Polybeads or ProteinG
beads, IFN-c responses were generally better at the higher dilution
(1:10,000.1:1,000.1:100) where background E. coli responses
were lower (Figures 7C–E). However, none of these IFN-c
responses were statistically different from the controls due to
variations in the cytokine levels between individuals (p,0.05 only
for EBNA3A-Protein G beads at 1:1000).
The profile of TNF-a responses by CBA was very similar to that
of IFN-c (Figure S3). For all viral antigens (except FluM-Ni-NTA),
TNF-a responses were statistically significant compared to controls
for cultures stimulated at 1:100 dilution with IVTT products
purified using NI-NTA resin (Figure S3A) or MagneHis Ni-
particles (Figure S3B). Responses were also significant at 1:1,000
dilutions for CMVpp65 and EBNA3 all purified using NI-NTA
resin or MagneHis Ni-particles; and FluHA purified with
MagneHis Ni-particles. The TNF-a profile was also similar to
that of IFN-c for unpurified and bead-associated IVTT products,
with the highest responses almost always detected at 1:10,000
(except for EBNA3) (Figures S3C-E). However, none of these
TNF-a responses were statistically significant (except for unpur-
ified CMVpp65 at 1:10,000), as noted above for IFN-c. The
overall level of TNF-a was enhanced by association to Polybeads
and Protein G beads, relative to unpurified IVTT products (up to
7-fold with EBNA3A-Polybeads at 1:100 dilution).
The profile of IL-10 responses by CBA was very similar to that
of IFN-c and TNF-a (Figure S4) for cultures stimulated with
IVTT products purified using NI-NTA resin (Figure S4A) or
MagneHis Ni-particles (Figure S4B) with the best responses
detected at 1:100 (Figure S4). However, for unpurified or bead-
associated IVTT products, the IL-10 profile was inverse to that of
Figure 7. Antigen-specific IFN-c CBA responses by human PBMC stimulated with IVTT-proteins. PBMCs were cultured with IVTT-
produced FluM, FluHA, CMVpp65 and EBNA3A purified using (A) NI-NTA nickel resin or (B) MagneHis Ni-particles; (C) unpurified; associated to (D)
Polybeads or (E) ProteinG beads; diluted 1:100, 1:1000 or 1:10,000. Negative controls were medium only, unpurified empty pIVEXHisHA IVTT extract,
and empty pIVEXHisHA IVTT extract associated to polybeads or protein G beads. Positive controls were CEF peptide pool or PHA (data not shown).
Secreted IFN-c in the supernatant of cultured PBMCs was analysed by Cytometric Bead Array after 72 hrs stimulation. * P,0.05 compared to negative
controls.
doi:10.1371/journal.pone.0027666.g007
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IFN-c and TNF-a with the best responses at a 1:100 dilution
(Figures S4C-E), consistent with potential immunosuppressive
effects of IL-10. Significant response was found only in EBNA3A
1:100 purified with MagneHis Ni-particles. As noted for TNF-a,
the overall level of IL-10 was enhanced by association to
Polybeads and Protein G beads relative to unpurified IVTT
products (up to 7-fold with EBNA3A-Polybeads at 1:100 dilution).
Responses for other cytokines assayed by CBA were not significant
(data not presented).
In summary, consistent with the murine data, robust antigen-
specific IFN-c and TNF-a responses from human PBMCs could
be induced following in vitro stimulation with IVTT products
purified by either NI-NTA resin or MagneHis Ni-particles. In
contrast to the murine system, positive IFN-c and TNF-a
responses to some antigens could also be induced by unpurified
IVTT reactions or IVTT products associated to Polybeads or
Protein beads, indicating that the E. coli and LPS background of
the whole extract was not sufficient to mask the immunogenicity
generated by the IVTT recombinant products. For some but not
all of the evaluated antigens, association of IVTT products to
Polybeads or Protein G beads enhanced the antigenicity about 2-
fold to 4-fold.
Discussion
The rapidly growing amount of genetic and proteomic
information available in the post-genomic era precludes the use
of traditional cell-based protein expression systems to screen
proteins of interest for their potential as vaccine targets. The
development of cell-free based systems, first described in 1960’s
[26], allows the high throughput recombinant expression of
thousands of proteins in reduced volume and time. The most
popular cell-free systems are based in E. coli, wheat germ and
rabbit reticulocytes extracts [4,5,27]. This platform has been
applied in a number of proteomics-based studies including
structural and functional proteomics [28,29,30], protein evolution
[31], unnatural amino acids and protein labeling [32,33], protein
interaction [34], diagnostics and therapeutics [35,36] and protein
microarrays [15,37,38,39]. The protein microarray platform,
exploiting antigen-specific antibodies present in plasma or sera
from exposed or immunized animals or humans, has been of
particular interest to our laboratory to identify potential target
antigens for malaria vaccine development [10,11,40]. Although
Plasmodium proteins have proven particularly difficult to express
using conventional cell-based methods, efficient expression of
P. falciparum proteins ($ 93%) has been obtained using the E. coli
cell-free system [11]. The wheat germ system has been also used
for production of P. falciparum proteins, but with less efficiency
(75%) [12].
The success with cell-free protein expression suggest that this
system could be also applied to cellular screening, to identify
antigenic targets of T cell responses from genomic sequence data.
However, this has not yet been adequately explored despite that T
cells play a central role in orchestrating acquired immunity against
infectious diseases [41,42]. Both CD8+ and CD4+ T cells can
mediate their effector function directly via cytotoxicity or
indirectly via cytokines. CD4+ T cells can also provide help for
CD8+ T cells or can recruit and activate B cells for antibody
secretion. To date, the only reports have been restricted to
measurement of proliferative T cell responses in PBMCs of
smallpox vaccines or of cattle immunized with a purified Anaplasma
marginale outer membrane preparation to a small number of IVTT
produced vaccinia virus proteins or outer membrane proteins,
respectively [18,19,43]. Neither of those studies comprehensively
assessed and optimized the application of IVTT products for
large-scale or proteome-wide cellular screening. Accordingly,
herein, we report proof of concept for the potential of this
approach a strategy for proteome-wide identification of antigens
targeted by cell mediated immunity in both viral and parasite
models, using IVTT products with specimens from human and
mice.
Our human studies used well characterized antigens from EBV,
CMV and Influenza A virus. which are known to be targeted by
both CD4+ and CD8+ T cell responses and with defined T cell
epitopes [44]. The murine studies used the well characterized
sporozoite coat protein, the circumsporozoite protein (CSP), from
the P. yoelii rodent malaria parasite. We tested each IVTT antigen
individually and presented to T cells in different forms – either
unpurified, purified using NI-NTA resin or MagneHis Ni-
particles, or associated to Polybeads or ProteinG beads. Synthetic
peptides representing defined T cell epitopes from the respective
antigens were assayed in parallel as positive controls. The primary
immune readout was IFN-c production due to its crucial role in
protection or pathogenesis of complex diseases [45].
For all four viral and one parasite antigens tested in this study,
partial products were common. The production of partial
fragments in E. coli based IVTT reactions has been described
previously and attributed to a phenomena called translational
pausing but the presence of partial products did not adversely
affect immunogenicity or antigenicity [46]. Since the antigens
produced by E. coli based IVTT were at least partially insoluble,
simple techniques for purification, such as antibody coated beads,
were not effective. We therefore explored alternative purification
options including Ni-NTA affinity resin and MagneHis Ni-
particles. Both purification systems tested using denaturating
conditions proved efficient but a much higher product recovery
was obtained with the Ni-NTA resin as compared to the
MagneHis Ni-particles. Unexpectedly, with the eukaryotic based
insect cell-free system, the solubility of the recombinants increased
to almost 100%, but only two of the four proteins expressed in the
E. coli cell-free system could be expressed in the insect cell based
system, at least for the limited number of times expression was
attempted. These data suggest that further studies with the insect
cell-free system are warranted. Newer technologies of high
throughput purification such as affinity ZipTips (Millipore,
Ireland) and Ni-NTA plates (Qiagen, Valencia, CA) can facilitate
the purification process, but do not effectively deal with solubility
issues.
In both human/virus and murine/parasite models, IVTT
products purified by either NI-NTA resin or MagneHis Ni-
particles were highly effective inducers of antigen-specific IFN-c
and TNF-a responses in vitro. In the human/virus but not murine/
parasite model, antigen-specific IFN-c and TNF-a responses could
also be induced by unpurified IVTT reactions or IVTT products
associated to Polybeads or Protein beads, indicating that the E. coli
and LPS background of the whole extract was not sufficient to
mask the immunogenicity of the IVTT recombinant products.
Addition of carboxylate beads to unpurified IVTT products
increased the immunogenicity of the IVTT viral products by up
1.8-fold for IFN-c, 2.6-fold for IL-10 and 7-fold for TNF-a. The
most robust and specific antigen-specific IFN-c and TNF-a
responses (by CBA) were detected at the highest dilution of IVTT
product, where background E. coli responses were lowest. This is a
favorable scenario for proteomic-wide scale cellular screening, as
the use of highly diluted IVTT products is more cost-effective.
Unexpectedly, poor results were obtained with ELIspot wells pre-
coated with anti-IFN-c mAb as well as anti-HIS mAb to bind the
HIS tag on the IVTT product. In vivo studies with PyCSP IVTT
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products confirmed that the target protein was produced and that
the IVTT produced proteins were immunogenic.
These data demonstrate the potential of IVTT products as a
useful tool for the proteome-wide screening of cellular targets of
viral, parasitic or bacterial immunity Overall, IVTT products
affinity purified through nickel resin or magnetic beads proved the
most efficient inducers of sensitive and specific antigen-specific
cytokine responses, the nickel resin method was associated with the
greater yield post-purification. Although not specifically evaluated
herein, it is likely that such cell-free approaches may be suited to
the identification of targets of CD4+ T cell responses, but not
targets of CD8+ T cell responses due to a requirement for target
antigen processing and presentation [43,47,48]. Rather, epitope-
based approaches based on prediction of high affinity binding class
I T cell epitopes using computerized algorithms, such as that
reported by us previously [49] are probably more appropriate.
Overall, the work reported here provides proof of concept for
the potential for high-throughput identification from genomic
sequence data of antigenic targets of T cell responses from
complex pathogens which threaten public health. Such antigens
may represent promising candidates for the development of
vaccines that have thus far proved elusive.
Materials and Methods
Human subjects
Ten healthy adult Caucasian volunteers (five male and five
female; mean age 36.367.1 years old) were recruited with written
informed consent under a protocol (P1111) approved by the
Queensland Institute of Medical Research Human Research
Ethics Committee. All studies with human specimens were
approved by the Queensland Institute of Medical Research
Human Research Ethics Committee (P1111) and conducted in
compliance with all applicable regulations governing protection of
human subjects. Although the history of vaccination in these
subjects has not been documented, it is likely that all would have
been vaccinated against or exposed to influenza, EBV, and CMV,
given the documented prevalence of these viruses in human
populations; and all were known to respond to the CEF peptide
pool which comprises CD8+ T cell epitopes from FLU, EBV and
CMV.
Animals
Female BALB/c (H-2d) mice aged 6-8 weeks were purchased
from The Animal Resource Centre (Perth, WA) and maintained
under standard conditions. All studies were approved by the
Queensland Institute of Medical Research Animal Ethics
Committee (protocol P1111).
Plasmid DNA
The plasmid DNA vaccines encoding the P. yoelii circumspor-
ozoite protein (CSP; VR2516) and the control plasmid (VR1020)
have been previously described [50,51]. The DNA vaccines were
prepared using the EndoFree Plasmid Mega Kit (Qiagen, Valencia,
CA) according to manufacturer’s instructions and administered in
sterile saline.
Protein expression vector
A custom vector was developed for protein expression in the E. coli
cell-free transcription translation system. This vector, called pIVEX
HisHA AmpR, was modified from the commercially available
pIVEX 2.4d and pIVEX 2.5d vectors (Roche Applied Science,
Mannheim, Germany) by incorporating both the N-terminal HIS
tag and C-terminal HA tag into the one vector backbone. The HA
tag was released from pIVEX 2.5d by digestion with BamHI and
XmaI restriction enzymes (New England Biolabs, Ipswich, MA) for
4 hrs at 37uC (1 mg DNA/1 unit enzyme, 20 ml volume) and the
fragment then extracted from a 3% agarose gel and purified using a
commercially available QIAquick PCR purification kit (Qiagen,
Germany) according to manufacturer’s instructions. The purified
HA-tag was ligated overnight at 16uC into BamHI and XmaI digested
pIVEX 2.4d vector using 400 units T4 ligase (New England Biolabs),
25 ng of linearized pIVEX 2.4d vector and 70 ng of the HA-tag
insert in a 20 ml reaction. The ligated product was purified from a
1% agarose gel as described above, transformed into TOP10
thermocompetent cells (Invitrogen), and grown on LB plates in the
presence of 100 mg/ml ampicillin. Positive colonies were screened by
colony PCR using 0.2 units/ml Expand Taq polymerase in Buffer 2
(Roche Diagnostics), 0.4 mM dNTPs and 0.4 mM each primer
(forward: TAATACGACTCACTATAGGG; reverse TGCTAGT-
TATTGCTCAGCGG) using the following conditions: initial
denaturation at 95uC for 5 min; 35 cycles at 95uC for 30 sec,
55uC for 30 sec and 68uC for 1 min; and a final extension at 68uC
for 10 min.
Recombinant protein constructs of FluM, FluHA,
CMVpp65, EBNA3A and PyCSP
For cloning the target genes into the customized pIVEX HisHA
vector, the complete open read frames of the Influenza matrix
protein (FluM; Influenza A virus A/Puerto Rico/8/34 strain,
accession#AF389121), Influenza haemagglutinin protein (FluHA;
Influenza A virus A/Puerto Rico/8/34 strain, accession
#AF389121), Cytomegalovirus phosphoprotein 65 (CMVpp65;
human herpesvirus 5 strain AD169, accession #P06725), Epstein
Barr Virus nuclear antigen 3A (EBNA3A; human herpesvirus 4
type 1 B95-8 accession #NC_007605) and P. yoelii circumspor-
ozoite protein (PyCSP; strain 17XNL, accession #J02695) were
amplified by PCR using gene-specific primers flanked with
restriction enzyme sites (Table 1). The 50 ml PCR reaction
contained 0.2 units/ml Expand Taq polymerase in Buffer 2 (Roche
diagnostics), 0.4 mM dNTPs and 0.4 mM each primer and 50 ng
DNA template. PCR conditions were: initial denaturation at 95uC
for 5 min; 45 cycles at 95uC for 30 sec, 55uC for 30 sec and 68uC
for 3 min; and a final extension at 68uC for 10 min. The
fragments corresponding to the expected size were excised from a
1% agarose gel, purified using the QIAquick PCR purification kit
(Qiagen, Germany), and digested overnight at 37uC using the
restrictions enzymes for which the cutting site was present in the
flanking sequence. The pIVEX HisHA vector was also digested
overnight at 37uC with the same set of restriction enzymes. After
cleanup using the PCR purification kit, the gene fragments and the
linearized vector were ligated overnight at 16uC at an insert:vector
ratio of 1:20 using 30 ng of vector and 400 units T4 ligase (New
England Biolabs) in a 20 ml reaction volume. The ligation product
was transformed into TOP10 thermo-competent cells, grown
overnight at 37uC on LB ampicillin plates (100 mg/ml), and
colonies screened by PCR using the same protocol for the
customized vector, except that the extension time of the colony
PCR was increased to 3 min. One positive colony of each
construct was grown overnight at 37uC in LB containing
ampicillin (100 mg/ml) and the plasmid purified using the
QIAprep Spin Miniprep kit (Qiagen) according to manufacturer’s
instructions. In a few instances where the IVTT production was
poor, the DNA was further purified using phenol/chloroform
extraction and ethanol precipitation which improved the yield, but
this was not routinely done. All constructs were confirmed by
DNA sequencing before use in the IVTT reactions.
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Recombinant protein expression
Recombinant proteins were synthesized by cell-free in vitro
transcription and translation using the Rapid Translation System
100 E. coli HY kit (Roche Diagnostics) or EasyXpress Insect Cell
Protein kit (Qiagen) according to the manufacturer’s instructions.
In some experiments, protease inhibitor cocktails (Cat P2714,
Sigma-Aldrich, St Louis, MO; Cat 1836170, Roche Diagnostics),
or addition of non-ionic detergents (Triton X-110 or Triton X-
114) were added according to manufacturer’s recommended
protocol: 4 hr at 25uC. The recombinant antigens were stored
at 220uC and used as immunogens for in vitro and in vivo up to
one week after production. Protein expression of the full-length
product (as evidenced by immunoblot using the anti-HA C-
terminal tag mAb) was quantitated against an IVTT-produced
recombinant P. falciparum (PF14_0051) protein of known concen-
tration expressing the same N-terminal 6xHis and C-terminal HA
tags. Immunoblot images were acquired in TIF format and
analysed using the AnalySIS LS software (version 5.0; Soft
Imaging Systems GmbH, Germany).
Purification of IVTT recombinant products
The E. coli IVTT products were purified using two different
methods based on affinity to the N-terminal 6xHIS tag. One
method used mini-spin columns with a cellulose acetate filter
(Pierce, Rockford, IL) and NI-NTA resin (Qiagen). For that, 200 ml
of NI-NTA resin was added to a spin column connected to a
collection tube. The column was washed twice with 600 ml of milliQ
water and twice with 600 ml of Binding Buffer (50 mM NaH2PO4,
300 mM NaCl, 20 mM Imidazole and 8 M Urea pH 8) using
centrifugation at 1500 rpm for 2 min. Then 50 ml of IVTT reaction
was mixed with 700 ml of Binding Buffer and incubated at 4uC for
20 min in an orbital mixer, to solubilize the inclusion bodies. The
solubilized sample was added to a NI-NTA resin column and
incubated at 4uC for 30 min in an orbital mixer to maximize
protein binding to the resin. The flow-through was removed via
centrifugation at 1500 rpm for 2 mins and the column washed three
times with 700 ml of Binding Buffer. The recombinant was eluted
with 200 ml of Elution Buffer (50 mM NaH2PO4, 300 mM NaCl,
250 mM Imidazole and 8 M Urea pH 8) incubated at 4uC for
20 min in an orbital mixer before collection via centrifugation.
The second method of purification used the commercially
available MagneHis Protein Purification System (Promega,
Madison, WI) according to the manufacturer’s instructions. For
that, 50 ml of IVTT reaction was mixed with 700 ml of Binding
Buffer (100 mM HEPES, 20 mM Imidazole and 8 M Urea
pH 7.5) and incubated at 4uC for 20 min in an orbital mixer, to
solubilize the inclusion bodies. Then, 30 ml of MagneHis Ni-
particles was added to the sample and the mixture incubated at
room temperature for 2 min. The sample tubes were connected to
the MagneSphere Magnetic Separation Stand (Promega) and,
after 30 sec of binding, the flow through was removed and
discarded. The magnetic beads with bound protein were washed 3
times with 700 ml of Binding Buffer and the recombinant eluted in
200 ml of Elution Buffer (100 mM HEPES, 500 mM Imidazole
and 8 M Urea pH 7.5) incubated at 4uC for 20 min in an orbital
mixer before collection.
The eluted recombinants from both methods were dialyzed
against PBS (desalting step) using Amicon ultra 0.5 ml 3 kDa cut-
off centrifugal filters (Millipore, Ireland). For that, the centrifugal
filters were wet with 300 ml of PBS pH 7.0 before adding 200 ml of
the eluted protein. After 30 min of centrifugation at 14,000 rpm at
4uC, the volume of the protein was reduced to approximately
100 ml and 400 ml of PBS pH 7.0 were added. This process was
repeated four times and the resultant sample collected and stored
at 220uC.
Western blot
Protein expression was confirmed by western blot. IVTT
products were diluted 1:1 in 2x reducing sample buffer (125 mM
Tris pH 6.8, 4% SDS, 10% glycerol, 0.006% bromophenol blue,
2% beta-mercaptoethanol) and denatured at 95uC for 5 mins.
Samples (2.5 ml of E. coli IVTT whole extract or supernatant, and
5 ml of insect cell IVTT whole extract or supernatant) were run in
parallel with molecular weight standard (BenchMark pre-stained
protein marker, Invitrogen) on a 4–12% NuPage SDS Page gel
(Invitrogen, Carlsbad, CA, USA) at 120 V for 70 min. Samples
were transferred onto a PVDF membrane (Bio-Rad, Hercules,
CA) pre-wet with 100% methanol, using the BioRad Mini Trans-
Blot system at 100 V for 1 hr, according to manufacturer’s
instructions. Membranes were blocked with PBS containing 5%
skim milk powder overnight at 4uC with shaking, washed 3 times
with PBS containing 0.05% Tween20, then probed with anti-HIS
HRP (1:5000; Roche Diagnostics) or anti-HA HRP (1:500) (Roche
Diagnostics) for 1 hr at room temperature. Membranes were
Table 1. DNA sequences and primers.
Antigen
GenBank
accession
number
Strain/
Source Ref
Restriction enzyme /
Forward primer
Restriction enzyme /
Reverse primer
FluM AF389121.1 Puerto Rico/ H1N1
segment 7
[22] NotI / 59
GGGGCGGCCGCATGAGTCTTCTAACCGAGG 39
SalI / 59 GGGGTCGACGCTTGAACCGTTGCATCTG 39
FluHA AF389118.1 Puerto Rico/H1N1
segment 4
[22] NotI / 59
GGGGCGGCCGCATGAAGGCAAACCTACTGG 39
SalI / 59 CAGTGCAGAATATGCATCCGTCGACCCC 39
pp65 FJ527563.1 AD169/Human
herpesvirus 5
[23] NotI / 59 GAAGCGGCCGCATGGAG-
TCGCGCGGTCGCCGTTG 39
XhoI / 59 GGGCTCGAGACCTCGGTGCTTTTTGGGC 39
EBNA3A V01555.2 B95-8/Epstein-Barr
virus
[24] NotI / 59AAGGAAAAAAGCGGCCGC-
ATGGACAAGGACAGGCCG 39
SalI / 59 GGGGTCGACGGGCCTCATCTGGAGGAT 39
PyCSP FJ527563.1 L/Plasmodium yoelii [25] NotI /
59GGCCGCGGCCGCCTTCCAGGATATGGACAA 39
SalI / 59 TCGAGTCGACTATTAAAGAATACTAATAC 39
Footnote to Table 1: The complete open read frames of genes encoding the Influenza A virus matrix (FluM) or haemagglutinin (FluHA), Cytomegalovirus
phosphoprotein 65 (CMVpp65), Epstein Barr Virus nuclear antigen 3A (EBNA3A) and the Plasmodium yoelii circumsporozoite surface protein (PyCSP) were cloned into
pIVEX His HA vector using gene-specific forward and reverse primers containing specific restriction enzyme sites, as indicated. The source of each template and the
corresponding GenBank accession numbers are also listed.
doi:10.1371/journal.pone.0027666.t001
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washed 3 times with PBS containing 0.05% Tween before
developing with the Immun-StarTM HRP system (Bio-Rad)
according to manufacturer’s instructions. Exposure times for the
X-ray film (FujiFilm Corporation, Tokyo) varied from 5 sec to
4 min. Immunoblot images were acquired in TIF format and
analysed using the AnalySIS LS software (version 5.0; Soft
Imaging Systems GmbH, Germany).
Immunization of mice using the VR2516 PyCSP DNA
vaccine and PyCSP IVTT product
Mice (n = 5/group) were immunized intramuscularly in the
tibialis anterior muscle with 50 mg of VR2516 PyCSP DNA
vaccine or VR1020 negative control plasmid, two times at 3 week
intervals. Splenocytes were harvested from DNA immunized mice
or naı¨ve control mice (n = 5) at 3 weeks post-boost for in vitro T cell
assays using IVTT products. Serum was collected from select
groups for antibody assays. The potential toxicity of IVTT
products was assessed prior to use for in vitro stimulation of T cell
responses by culturing splenocytes (56105 cells/well) of naı¨ve
BALB/c mice with IVTT-produced PyCSP either unpurified or
purified using NI-NTA resin (Qiagen) or MagneHis particles
(Promega) at dilutions of 1:100, 1:1000 and 1:10000, or media
alone, and monitoring cell growth for 48 hours. No toxicity due to
the unpurified or purified IVTT preparations was apparent, as
indicated by cell death.
For the in vivo evaluation of IVTT products, mice (n = 5/group)
were immunized intramuscularly with 50 mg/100 ml of VR2516
PyCSP DNA vaccine (split between two legs) and boosted 3 weeks
later with PyCSP IVTT products formulated with 100 ml
Aluminium Hydroxide gel adjuvant (Brenntag Biosector, Freder-
ikssund, Denmark) as follows: A) 15 ml of IVTT reaction (9 mg
PyCSP/mouse); B) 15 ml of IVTT reaction purified through NI-
NTA resin (6.6 mg PyCSP/mouse); C) 15 ml of IVTT reaction
purified through MagneHis Protein Purification System (3 mg
PyCSP/mouse); D) 15 ml of IVTT reaction absorbed in 10 ml of
PolybeadH Poly(methyl methacrylate) microspheres (PMMA
microspheres, 0.08–0.09 mm diameter) (Cat #23570, Poly-
sciences, Inc., Warrington, PA, USA) (9 mg PyCSP/mouse); and
E) 15 ml of IVTT reaction associated to 10 ml of Protein G
conjugated microspheres/carboxylate beads (Cat #21106, Poly-
science) (9 mg PyCSP/mouse). The beads used in the immuniza-
tions were washed 3 times with PBS pH 7.0 before addition of the
IVTT product, and used without further processing. Positive and
negative controls groups (n = 5) were administered 50 mg of
VR2516 PyCSP DNA vaccine intramuscularly or 100 ml of Alum
mixed with 100 ml of PBS pH 7.0, respectively. Three weeks after
immunization mice were sacrificed and the spleens harvested for
use as effectors in T cell assays.
In vitro culture of murine splenocytes
Spleens were macerated, washed in Dulbecco’s solution contain-
ing 2% FCS, the red blood cells lysed with 0.09% NH4Cl for 5 min
at 37uC, and then washed again. The splenocytes were resuspended
in complete DMEM containing 10% FCS, 100 U/ml of Penicillin,
100 mg/ml of Streptomycin, 2 mM L-Glutamine and 0.05 mM
ß-mercaptoethanol, and cultured in 96-wells flat-bottomed plates
for ELIspot or CBA at a concentration of 56105 cells/well.
For in vitro evaluation of IVTT products, splenocytes were
stimulated with unpurified rPyCSP IVTT; rPyCSP IVTT
associated to Polybeads or ProteinG beads; or rPyCSP IVTT
purified using NI-NTA resin or MagneHis Ni-particles. Unpur-
ified IVTT products were used at a dilution of 1:200 or 1:1000
and purified IVTT products were used at a dilution of 1:100 or
1:200 for evaluation of cytokines in the supernatant using the
Cytometric Bead Array assay or IFN-c secreting cells via ELIspot,
respectively. Pilot experiments were carried out to find out the
optimal dilutions of IVTT products for these assays (data not
shown). An IVTT reaction using the empty pIVEX HisHA
vector was used as negative control. A pool of synthetic peptides
representing defined CD4+ and CD8+ T cell epitopes from PyCSP
(residues 57–70, sequence KIYNRNIVNRLLGD [52]; residues
280–288, sequence SYVPSAEQI [53]; and resides 280–295,
sequence SYVPSAEQILEFVKQI [54]) at 10 mg/ml of each
peptide was used as a positive control. ConA (Sigma-Aldrich,
St. Louis, MO) at 5 mg/ml was used as a mitogen control. All
stimuli were added in association with 16105 cells/well of A20/2 J
cells (ATCC clone HB-98) irradiated at 1600 rads, as antigen
presenting cells.
For in vivo evaluation of IVTT products, splenocytes were
stimulated with 26104 cells/well of A20 cells transfected with
VR2516 PyCSP DNA or VR1020 negative control using the
AMAXA Nucleofector transfection kit (AMAXA, Cologne,
Germany) according to manufacturer’s manual, or with 16105
cells/well of A20 cells pulsed with the PyCSP peptide pool. A20
cells alone and medium were used as negative controls and ConA
used as mitogen control. AMAXA transfections included parallel
reactions with GFP plasmid as a positive control (data not
presented); additionally, our laboratory routinely uses AMAXA-
transfected A20 cells as APCs for in vitro T cell assays [55,56].
In vitro culture of human PBMCs
Peripheral blood mononuclear cells (PBMC) were isolated using
standard Ficoll density gradient centrifugation and resupsended in
complete RPMI containing 10% human AB serum, 100 units/ml
of Penicillin, 100 mg/ml of Streptomycin, 2 mM L-Glutamine, 1
mM Sodium Pyruvate and 25 mM Hepes. Cells were cultured at a
concentration of 16105 cells/well in 96-wells round-bottomed
plates at 37uC in an atmosphere of 5% CO2. The cells were
stimulated with IVTT-produced FluM, FluHA, CMVpp65 and
EBNA3A antigens, either unpurified; associated to Polybeads or
ProteinG beads; or purified using NI-NTA resin or MagneHis Ni-
particles. Unpurified and purified IVTT products were used at a
dilution of 1:100, 1:1000 or 1:10000 for evaluation of cytokines in
the supernatant using the Cytometric Bead Array assay, or at a
dilution of 1:1000 (unpurified) or 1:100 (purified) for evaluation of
IFN-c secreting cells via ELISpot. Negative controls included
empty pIVEX HisHA IVTT reaction alone or associated to
Polybeads or ProteinG beads, or medium only. A CEF peptide
pool consisting of 32 synthetic peptides representing defined CD8+
T cell epitopes from human Cytomegalovirus, Epstein-Barr Virus
and Influenza Virus (Anaspec, San Jose, CA) at 5 mg/ml total was
used as a positive control [44]. Phytohemagglutinin (PHA; Sigma-
Aldrich, St. Louis, MO) at 2 mg/ml was used as a mitogen control.
IFN-c ELIspot assay
IFN-c secreting T cells were enumerated by ELISpot. Briefly,
MultiScreen HTS IP 96 plates (Cat MSIPS4510, Millipore,
Ireland) were pre-wet with 15 ml/well of 35% ethanol and washed
twice with PBS (pH 7.4). For mouse ELIspot assays, wells were
coated with 75 ml/well of sterile PBS (pH 7.4) containing 10 mg/
ml anti-mouse IFN-c (Cat 551216, Clone R4-6A2, BD Pharmin-
gen, CA) with or without 1:500 anti-His mAb (Cat H1029, Sigma-
Aldrich, St. Louis, MO) overnight at room temperature. For
human ELIspot assays, wells were coated with 75 ml/well of
carbonate buffer (pH 9.6) containing 10 mg/ml anti-human IFN-c
(Cat 3420-3, Clone 1-D1K, MABTECH, Sweden) with or without
1:500 anti-His mAb (Cat H1029, Sigma-Aldrich, St. Louis, MO)
overnight at 4uC. Plates were washed twice with 200 ml/well
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DMEM (splenocytes) or RPMI (PBMC) and blocked with 200 ml/
well of medium containing 10% FCS for 3 hrs at 37uC. After
blocking, the wells coated with anti-His mAb were incubated with
PyCSP, FluM, FluHA, CMVpp65, EBNA3A or empty pIVEX
HisHA IVTT products diluted 1:1000 in DMEM or RPMI
containing 2% FCS in a volume of 50 ml/well, overnight at 4uC
(to absorb the His-tagged IVTT products to the anti-His mAb
coated wells). Plates were washed 3 times with DMEM or RPMI,
and the cells added to the IFN-c and His coated wells in triplicates.
Alternatively, in the absence of anti-His pre-coating, IVTT
products unpurified, associated to Polybeads or ProteinG beads,
or purified using NI-NTA resin or MagneHis Ni-particles (see
above), were added to the IFN-c coated wells together with the
cells (100,000 PBMCs or 500,000 splenocytes), in triplicate. After
36 hrs incubation, plates were flicked to remove the cells and
washed 6 times with PBS-Tween 0.05% pH 7.4 (PBS-T). Then
75 ml/well of biotinylated anti-mouse IFN-c (Cat 554410, Clone
XMG1.2, BD Pharmingen) at 2 mg/ml in PBS or 75 ml of
biotinylated anti-human IFN-c (Cat 3420-6, Clone 7-B6-1,
MABTECH, Sweden) diluted 1:1000 in PBS was added to each
well. Plates were incubated for 3 hrs at room temperature, washed
3 times with PBS-T, and 75 ml/well of Streptavidin-HRP for
splenocytes cultures or Streptavidin-AP (Bio-Rad, Hercules, CA)
for PBMC cultures diluted 1:1000 in PBS was added. After 1 hour
incubation at room temperature, plates were washed 3 times with
PBS-T followed by 3 times with PBS alone, and developed using
the AEC substrate set (BD Pharmingen) for mouse splenocytes or
SigmaFast BCIP/NBT (Sigma-Aldrich) for humans PBMC
cultures, according to manufacturer’s instructions. After 10 mins,
the plates were rinsed extensively with dH2O to stop the
enzymatic reaction, dried and stored in the dark. The number
of IFN-c secreting cells was determined using the automated
ELISpot reader (AID iSpot Reader, Autoimmun Diagnostika
GmbH, Strassberg, Germany).
Cytometric Bead Array assay
To determine the cytokines secreted by the stimulated
splenocytes or PBMC, cells were cultured at a concentration of
56105 cells/well in 96-wells flat-bottomed plates (Corning
Incorporated, Corning, NY, USA). The supernatant was collected
after 48 hrs and 72 hrs stimulation and analyzed with Cytometric
Beads Array flex kits (BD Biosciences, San Jose, CA, USA)
containing IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13,
IFN-c and TNF-a for mouse and IL-10, IFN-c and TNF-a for
human samples. Data were acquired and analyzed using BD
FACS Array Bioanalyser and FlowJo 7.6 software.
ELISA
PyCSP-specific antibody responses in mouse sera were evaluated
by peptide ELISA, as previously described [57]. Briefly, flat-
bottomed 96-well microtiter plates (Immulon 4; Dynex Technol-
ogy Inc., Chantilly, VA, USA) were coated with 100 ml/well of
recombinant PyCSP protein at a concentration of 1 mg/ml in
carbonate-bicarbonate coating buffer pH 7.4, and incubated
overnight at 4uC. Wells were blocked for 1 hr with 2% BSA in
PBS containing 0.05% Tween 20 (Blocking Buffer) and washed
three times with PBS containing 0.05% Tween 20 (PBS-T).
Consecutive dilutions of individual sera diluted in PBS containing
0.01% Tween-20 were incubated for 2 hrs at room temperature.
The plates were washed 3 times, and incubated with 100 ml/well
Biotinylated anti-mouse IgG (Jackson ImmunoResearch) at a
dilution of 1:20,000 for 1 hr. The plates were washed three times
and incubated with Streptavidin HRP (BD Biosciences) at a
dilution of 1:1000 for 1 hr. The plates were washed and developed
for 10 mins with 50 ml/well TMB substrate (Sigma). Reactions
were terminated by adding 50 ml of stopping buffer and the
OD450 recorded using a VersaMax microplate reader (Molecular
Devices, Sunnyvale, CA, USA). Results are expressed as mean OD
readings of triplicate wells +/- SE.
Statistical analysis
Data from the in vitro and in vivo tests in mice were analyzed by
the Student t-test and two-way ANOVA, respectively, where a p
value,0.05 was considered significant. Data from human PBMC
ELIspot and CBA were analyzed using two-way ANOVA and
one-way ANOVA, respectively. A p value,0.05 was considered
significant.
Supporting Information
Figure S1 Recombinants produced using E. coli cell-
free IVTT system. Western Blot of (A) viral antigens FluM (32
kDa), FluHA (68 kDa), CMVpp65 (68 kDa) and EBNA3A (108
kDa), and parasite protein PyCSP (44 kDa), probed with anti-HA
antibody, and (B) viral antigens FluM, FluHA, CMVpp65 and
EBNA3A probed with anti-His antibody. Whole IVTT extracts
(5 ml) of each antigen were run on a 12% NUPAGE gel,
transferred to a PVDF membrane, and probed with anti-HA
HRP antibody (1:500 dilution) or anti-His HRP antibody (1:5000
dilution). The western probed with anti-HA also detected a cross
reactive band of 56 kDa in all expression extracts. The western
probed with anti-His mAb showed the presence of partial products
probably due to early termination of translation.
(TIF)
Figure S2 Antigen-specific TNF-a and IL-10 responses
of mouse splenocytes stimulated in vivo or in vitro with
IVTT-proteins. (A) and (B): splenocytes of mice immunized with
VR2516 PyCSP plasmid DNA or VR1020 control DNA were
cultured in vitro with unpurified rPyCSP IVTT; rPyCSP IVTT
associated to Polybeads or ProteinG beads; rPyCSP IVTT purified
using NI-NTA resin, MagneHis Ni-particles, or anti-HIS; or
synthetic peptides representing defined T cell epitopes from
PyCSP (positive control), as indicated. (C) and (D): splenocytes of
mice immunized with VR2516 PyCSP plasmid DNA and boosted
in vivo with unpurified rPyCSP IVTT; rPyCSP IVTT associated to
Polybeads or ProteinG beads; or rPyCSP IVTT purified using NI-
NTA resin or MagneHis Ni-particles; all formulated with Alum
adjuvant. Parallel groups of mice were boosted with either Alum
only or VR2516 as controls. Splenocytes were cultured in vitro with
A20 cells transfected with VR2516 PyCSP plasmid DNA or A20
cells pulsed with synthetic peptides representing defined PyCSP T
cell epitopes, as indicated. Secreted TNF-a (A and C) or IL-10 (B
and D) in culture supernatant was measured by Cytometric Bead
Array (CBA) after 48 hrs stimulation. *P,0.05, **P,0.01 and
***P,0.001 compared to negative controls.
(TIF)
Figure S3 Antigen-specific TNF-a responses by human
PBMC stimulated with IVTT-proteins. PBMCs were
cultured with IVTT-produced FluM, FluHA, CMVpp65 and
EBNA3A purified using (A) NI-NTA nickel resin or (B) MagneHis
Ni-particles; (C) unpurified; associated to (D) ProteinG beads or
(E) Polybeads; or (F) added to wells precoated with Anti-His;
IVTT products were diluted 1:100, 1:1000, or 1:10,000. Secreted
TNF-a in the supernatant of cultured PBMCs was analyzed
by Cytometric Bead Array after 48 hrs stimulation. * P,0.05
compared to negative controls.
(TIF)
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Figure S4 Antigen-specific IL-10 responses by human
PBMC stimulated with IVTT-proteins. PBMCs were
cultured with IVTT-produced FluM, FluHA, CMVpp65 and
EBNA3A purified using (A) NI-NTA nickel resin or (B) MagneHis
Ni-particles; (C) unpurified; associated to (D) ProteinG beads or (E)
Polybeads; or (F) added to wells pre-coated with Anti-His; IVTT
products were diluted 1:100, 1:1000, or 1:10,000. Secreted IL-10
in the supernatant of cultured PBMCs was analyzed by
Cytometric Bead Array after 48 hrs stimulation. * P,0.05
compared to negative controls.
(TIF)
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